Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer

Pancreas

Volumn 40, Issue 3, 2011, Pages 410-414

  Ruiz Rabelo, Juan ^a   Vázquez, Reyes ^a   Arjona, Álvaro ^a   Perea, Dolores ^a   Montilla, Pedro ^b   Túnez, Isaac ^b   Muntané, Jordi ^a,c   Padillo, Javier ^c,d  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

capecitabine; melatonin; pancreas cancer

Indexed keywords

BIS(2 OXOPROPYL)NITROSAMINE; CAPECITABINE; LIPID PEROXIDE; MELATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; HAMSTER; MALE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIOXIDANTS; CRICETINAE; DEOXYCYTIDINE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUOROURACIL; LIPID PEROXIDES; MALE; MELATONIN; MESOCRICETUS; NITROSAMINES; PANCREATIC NEOPLASMS; PRODRUGS;

EID: 79954418308     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318201ca4f     Document Type: Article

References (48)

1. Beger HG, Rau B, Gansauge F, et al. Treatment of pancreatic cancer: challenge of the facts. World J Surgery. 2003;27:1075-1084. (Pubitemid 37259985)
2. Yeo CJ, Hruban RH, Conlon KC, et al. Pancreatic cancer. J Am Coll Surg. 1998;187:429-442.
3. Yeo CJ, Cameron JL, Sohn TA. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s. Pathology, complications, and outcomes. Ann Surg. 1997;226:248-260.
4. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363: 1049-1057. (Pubitemid 38410779)
5. Iacobuzio-Donahue CA, Hruban RH. Gene expression in neoplasms of the pancreas: applications to diagnostic pathology. Adv Anat Pathol. 2003;10:125-134.
6. Bockman DE, Guo J,Büchler P, et al. Origin and development of the precursor lesions in experimental pancreatic cancer in rats. Lab Invest. 2003;83:853-859.
7. Stadtman RE. Protein oxidation and aging. Science. 1992;245:1220-1224.
8. Termini J. Hydroperoxide-induced DNA damage and mutations, Mutat Res. 2000;45:107-124. (Pubitemid 30323637)
9. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 2000;21:361-370. (Pubitemid 30137921)
10. Burcham PC. Genotoxic lipid peroxidation products: their DNA-damaging properties and role in formation of endogenous DNA adducts. Mutagenesis. 1998;13:287-305. (Pubitemid 28243164)
11. D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin. 2005;55:319-321. (Pubitemid 41377335)
12. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004;3:294-300. (Pubitemid 39552423)
13. Rosen J, Than NN, Koch DK, et al. Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res. 2006;41:374-381. (Pubitemid 44498224)
14. Tan DX, Manchester LC, Terron MP, et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42:28-42.
15. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res. 2004;37:213-214. (Pubitemid 39274120)
16. Ruiz-Rabelo JF, Va?zquez R, Perea MD, et al. Beneficial properties of melatonin in an experimental model of pancreatic cancer. J Pineal Res. 2007;43:270-275. (Pubitemid 47354139)
17. Smith DB, Neoptolemos JP. Capecitabine in carcinoma of the pancreas. Exp Opin Pharmacother. 2006;7:1633-1639. (Pubitemid 44209606)
18. Takebayashi Y, Yamada K, Miyadera K, et al. The activity and expression of thymidine phosphorylase in human solid tumors. Eur J Cancer. 1996;32:1227-1237.
19. Hess V, Salzberg M, Borner M. Combining capecitabine and gemcitabine in patient with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2003;21:66-68.
20. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212-2217. (Pubitemid 46954645)
21. Boeck S, Hoehler T, Seipelt G, et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol. 2008;19:340-347. (Pubitemid 351201717)
22. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007;25:4787-4792. (Pubitemid 350086482)
23. Roy S, Bell D, Russo S, et al. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J. 2007;13:247-256.
24. Meijers M, Van Garderen-Hoetmer A, Lamers CB, et al. Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters. Carcinogenesis. 1990;11:2223-2226.
25. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988;34:479-500.
26. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-126.
27. Flohé L, Gunzler WA. Assays of glutathione peroxidase. Methods Enzymol. 1984;105:114-121.
28. Dreher D, Junod AF. Review: role of oxygen free radicals in cancer development. Eur J Cancer. 1996;32:30-38.
29. Dianzani MU. Lipid peroxidation and cancer. Crit Rev Oncol Hematol. 1993;15:125-147. (Pubitemid 24013566)
30. Pour P, Althoff J, Kru?ger FW, et al. A potent pancreatic carcinogen in Syrian golden hamster: N-nitroso-bis(2-oxopropyl)amine. J Natl Cancer Inst. 1977;58:1449-1453. (Pubitemid 8094251)
31. Pour PM, Runge RG, Birt D, et al. Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to the human disease. Cancer. 1981;47:1573-1587.
32. Wenger FA, Kilian M, Achucarro P, et al. Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology. 2002;2:54-60. (Pubitemid 34639103)
33. Wenger FA, Kilian M, Ridders J, et al. Influence of antioxidative vitamins A, C and E on lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Prostagland Leukot Fatty Acids. 2001;65:165-171. (Pubitemid 33095965)
34. Woutersen RA, Appel MJ, Van Garderen-Hoetmer A. Modulation of pancreatic carcinogenesis by antioxidants. Food Chem Toxicol. 1999;37:981-984. (Pubitemid 29481801)
35. Wenger FA, Kilian M, Jacobi CA, et al. Effects of octreotide on liver metastasis and intrametastatic lipid peroxidation in experimental pancreatic cancer. Oncology. 2001;60:282-288. (Pubitemid 32424535)
36. Wenger FA, Killian M, Mautsch I, et al. Influence of octreotide and tamoxifen on tumor growth and liver metastasis in N-nitrosobis(2-oxopropyl) amine-induced pancreatic cancer in Syrian hamsters. Horm Res. 2000;54:74-77. (Pubitemid 32225736)
37. Saif MW, Kang SP, Ledbetter L, et al. Long-term survival on capecitabine in two gemcitabine-refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? J Pancreas. 2007;8:799-805. (Pubitemid 350200200)
38. Saif MW, Moody JS, Russo SM. Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer. JOP. 2005;6:325-333.
39. McGinn CJ, Chang AE, Colletti LM, et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63:1325-1330. (Pubitemid 41628025)
40. Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2008;61:167-175. (Pubitemid 47512638)
41. Schuller J, Cassidy J, Dumont E. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291-297. (Pubitemid 30151522)
42. Anisimov VN, Alimova IN, Baturin DA, et al. The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Int J Cancer. 2003;103:300-305. (Pubitemid 36076422)
43. Kubatka P, Kalicka K, Chamilova M, et al. Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats. Neoplasma. 2002;49:255-259.
44. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1-9. (Pubitemid 38130283)
45. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res. 2005;39:99-104. (Pubitemid 41140746)
46. Peschke E, Frese T, Chankiewitz E, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 2006;40:135-143.
47. Muhlbauer E, Peschke E. Evidence for the expression of both the MT1- and in addition, the MT2-melatonin receptor, in the rat pancreas, islet and beta-cell. J Pineal Res. 2007;42:105-106. (Pubitemid 44924332)
48. Moss RW. Do antioxidants interfere with radiation therapy for cancer? Integr Cancer Ther. 2007;6:281-292.